Teladoc Health (TDOC) Releases Q4 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its fourth quarter earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of ($0.38)-($0.36) for the period, compared to the Thomson Reuters consensus estimate of ($0.34). The company issued revenue guidance of $119-$121 million, compared to the consensus revenue estimate of $117.50 million.

A number of analysts recently issued reports on the company. KeyCorp increased their price objective on Teladoc Health from $90.00 to $94.00 and gave the stock an overweight rating in a report on Friday, September 28th. TheStreet cut Teladoc Health from a c rating to a d+ rating in a report on Tuesday, October 9th. Chardan Capital increased their price objective on Teladoc Health from $73.00 to $86.00 and gave the stock a buy rating in a report on Friday, August 3rd. Robert W. Baird increased their price objective on Teladoc Health from $50.00 to $65.00 and gave the stock a neutral rating in a report on Wednesday, July 25th. Finally, Canaccord Genuity reissued a buy rating and set a $70.00 price objective on shares of Teladoc Health in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Teladoc Health presently has a consensus rating of Buy and a consensus price target of $82.95.

Shares of NYSE:TDOC traded up $2.99 on Friday, hitting $72.51. The company’s stock had a trading volume of 3,376,871 shares, compared to its average volume of 2,039,709. Teladoc Health has a 1 year low of $27.30 and a 1 year high of $89.05. The stock has a market cap of $5.04 billion, a P/E ratio of -43.95 and a beta of 0.96. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.58.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Thursday, November 1st. The health services provider reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. Teladoc Health had a negative return on equity of 16.52% and a negative net margin of 31.32%. The firm had revenue of $111.00 million for the quarter, compared to analysts’ expectations of $109.94 million. During the same quarter last year, the firm posted ($0.55) EPS. The company’s revenue was up 61.6% compared to the same quarter last year. On average, equities research analysts expect that Teladoc Health will post -1.49 EPS for the current fiscal year.

In related news, insider Stephany Verstraete sold 18,000 shares of the firm’s stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $74.79, for a total transaction of $1,346,220.00. Following the transaction, the insider now directly owns 13,925 shares of the company’s stock, valued at approximately $1,041,450.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Lewis Levy sold 1,284 shares of the firm’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $77.00, for a total value of $98,868.00. Following the transaction, the insider now directly owns 1,284 shares in the company, valued at $98,868. The disclosure for this sale can be found here. In the last ninety days, insiders sold 166,706 shares of company stock worth $12,412,229. Insiders own 3.95% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply